TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05605691

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renuvion APR System
Description: The Renuvion Generator (K192867) is indicated for delivery of radiofrequency energy and/or helium plasma to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The Renuvion APR Handpiece (K191542) is intended to be used with compatible electrosurgical generators for the delivery of radiofrequency energy and/or helium plasma for cutting, coagulation and ablation of soft tissue during open surgical procedures.~Together, the Renuvion Generator and Handpiece are referred to as the Renuvion APR System.
Study: NCT05176873

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single oral dose of placebo will be given.
Study: NCT06006377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physiotherapy
Description: hotpack electrotherapy ultrasound exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physiotherapy
Description: hotpack electrotherapy ultrasound exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Backup therapy
Description: The backup spine health device is in the form of a mat and provides segmental electrical stimulation to the spines. At the same time, the mat can heat up to 40 degrees during the treatment process. Backup spine health device is very effective in both reducing pain and strengthening the muscles with electrical stimulations by reaching even the deep muscles around the spine. Sessions consist of 30 minutes
Study: NCT05311579

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Niraparib plus anlotinib
Description: Niraparib QD D1-21 plus Anlotinib 10mg QD D1-14 until disease progression or intolerable toxicity~21days/cycle
Study: NCT05303584

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5-nCoV-IH
Description: The orally aerosolized Ad5-nCoV is a replication defective Ad5 vectored COVID-19 vaccine expressing the full-length spike gene of wide-type SARS-CoV-2, Wuhan-Hu-1. The Ad5-nCoV vaccine was supplied in 1.5mL/vial, at a concentration of 1.0 × 1011 viral particles per mL as a liquid formulation. 0.1 ml of Ad5-nCoV vaccine will be aerosolized by using Continuous Vapouring System. Then, the aerosolized droplets will be poured into a disposable suction cup and be inhaled by participants through mouth.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5-nCoV-IM
Description: The Ad5-nCoV is a replication defective Ad5 vectored COVID-19 vaccine expressing the full-length spike gene of wide-type SARS-CoV-2, Wuhan-Hu-1. It was supplied in 1·5mL/vial, at a concentration of 1.0 × 1011 viral particles per mL as a liquid formulation. Participants will be administrated 0.5ml（5×1010VP）of Ad5-nCoV vaccine intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CoronaVac
Description: CoronaVac is an inactivated whole-virion vaccine with aluminium hydroxide as the adjuvant, prepared with a novel coronavirus (CZ02 strain) inoculated in African green monkey kidney cells (Vero cells). One dose of CoronaVac contains 3 μg of SARS-CoV-2 virion in a 0.5 mL aqueous suspension for injection with 0.45 mg/mL of aluminium.
Study: NCT05216055

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ropivacaine, Dexmedetomidine, Dexamethasone sodium phosphate, Normal saline
Description: Ropivacaine 0.5% HCl, 40 mL (5 mg per mL) (200 mg) Dexmedetomidine HCl, 0.50 ml (100 ug per mL) (50 ug) Dexamethasone sodium phosphate, 1 mL (10 mg per mL) (10 mg) Normal saline 0.9%, 18.5mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: Liposomal bupivacaine, 20 mL (13.3 mg/ml) (266 mg) Normal saline 0.9%, 40mL
Study: NCT06008899

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US assisted caudal epidural pulsed radiofrequency
Description: patients will receive US assisted caudal epidural pulsed radiofrequency and followed up to 8 weeks
Study: NCT06002984

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Using Neuromonitoring to find EBSLN
Description: intraoperative neuromonitoring to preserving external branch of superior laryngeal nerve during thyroid surgery
Study: NCT05812066

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: all ceramic single-retainer resin bonded fixed partial denture
Description: The intervention will be all ceramic single-retainer RBFPD using the upper canine as abutment with minimum preparation on the lingual surface within the enamel providing maximum area for the retainer bonding, to replace the upper lateral incisor and will be compared with the control/comparator group which is the all ceramic single-retainer RBFPD using the upper central incisor.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: all ceramic single-retainer resin bonded fixed partial denture
Description: The intervention will be all ceramic single-retainer RBFPD using the upper canine as abutment with minimum preparation on the lingual surface within the enamel providing maximum area for the retainer bonding, to replace the upper lateral incisor and will be compared with the control/comparator group which is the all ceramic single-retainer RBFPD using the upper central incisor.
Study: NCT05135481

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: phrenectomy
Description: The qualification for phrenectomy in group 1 will be made based on the Amir scale, i.e. a score of 4 and fewer points for the language function (2).
Study: NCT05750355

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TPN171H 10 mg Group
Description: 6 subjects will receive TPN171H 10 mg, orally; 2 subjects will receive placebo, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H 10 mg Group
Description: 6 subjects will receive TPN171H 10 mg, orally; 2 subjects will receive placebo, orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TPN171H 30 mg Group
Description: 6 subjects will receive TPN171H 30 mg, orally; 2 subjects will receive placebo, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H 30 mg Group
Description: 6 subjects will receive TPN171H 30 mg, orally; 2 subjects will receive placebo, orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TPN171H 40 mg Group
Description: 6 subjects will receive TPN171H 40 mg, orally; 2 subjects will receive placebo, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H 40 mg Group
Description: 6 subjects will receive TPN171H 40 mg, orally; 2 subjects will receive placebo, orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TPN171H 50 mg Group
Description: 6 subjects will receive TPN171H 50 mg, orally; 2 subjects will receive placebo, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H 50 mg Group
Description: 6 subjects will receive TPN171H 50 mg, orally; 2 subjects will receive placebo, orally.
Study: NCT05158868

Intervention type: DIAGNOSTIC_TEST
Intervention: HiF-1 alpha measurement
Description: HIF1- α is a heterodimeric transcription factor that bind to hypoxia response elements, which participates through the regulation of the expression of several genes in numerous cellular events such as O2 sensing, glucose metabolism, lipid metabolism, angiogenesis and other aspects of endothelial biology

Intervention type: DIAGNOSTIC_TEST
Intervention: HiF-1 alpha measurement
Description: HIF1- α is a heterodimeric transcription factor that bind to hypoxia response elements, which participates through the regulation of the expression of several genes in numerous cellular events such as O2 sensing, glucose metabolism, lipid metabolism, angiogenesis and other aspects of endothelial biology
Study: NCT05375695

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Description: The intervention consists of an 8-week strict time-restricted eating period, where participants follow the same 10-hour eating window (self-selected timing from 6 am to 8 pm) each day with minimal support to obtain lived experiences with challenges associated with time-restricted eating. Followed by an individually adjusted 4-week time-restricted eating period, including supporting components.~Staff will help participants select a time-interval that fits into their daily life. Diet is ad libitum and with no further dietary restrictions. The time-restricted eating intervention is an addition to standard care.
Study: NCT05781295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TaurolockTM
Description: The patient will be followed up to a maximum of 6 months after randomization after have a TaurolockTM injected each time catheter will be used.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Physiological serum
Description: The patient will be followed up to a maximum of 6 months after randomization after have a Physiological serum injected each time catheter will be used.
Study: NCT05237479

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suprainguinal fascia ilica block
Description: Patients who have been randomized to Group B Intervention will receive a preoperative S-FICB using 35ml of 0.5% ropivacaine under ultrasound guidance by the regional anesthesia block team once patient has been marked by surgeon. Sensory \& motor distribution of the LFCN, FN, \& ON will be assessed by the regional anesthesia team in the preop area for patients randomized to the control group prior to surgery. Patients who received a S-FICB in preop, approximately 15 minutes after the block, sensory \& motor distribution of LFCN, FN, \& ON will be assessed by the regional anesthesia block team prior to going to the operating room. All patients, regardless of group allocation, will be followed by the acute pain service team on postoperative day one to assess sensory \& motor distribution of LFCN, FN, \& ON \& adjustment of pain medication regimens. All patients will receive a call from a research assistant blinded to group allocation 24 hours post-discharge for a patient satisfaction survey.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The sensory and motor distribution of the LFCN, FN, and ON will be assessed by the regional anesthesia team in the preop area for patients randomized to the control group prior to surgery.
Study: NCT05466747

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RYMPHYSIA
Description: RYMPHYSIA administered through an IV injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RYMPHYSIA
Description: RYMPHYSIA administered through an IV injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RYMPHYSIA
Description: RYMPHYSIA administered through an IV injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Another Available A1PI
Description: Another available A1PI administered through an IV injection.
Study: NCT05778786

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acuvue Oasys 1 Day for Astigmatism
Description: CONTROL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acuvue Oasys 1 Day for Astigmatism
Description: CONTROL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRA100/TRA200 series toric contact lens with HEVL-blocking chromophore
Description: TEST

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRA100/TRA200 series toric contact lens with HEVL-blocking chromophore
Description: TEST
Study: NCT05384067

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention
Description: Participants will complete one mindfulness education module every week for 4 weeks, and to practice a 15-minute formal guided mindfulness meditation at least five times per week across the 4 weeks. Participants will also be taught evidence-based sleep improvement techniques, will be provided education for when to use the techniques, and will be encouraged to implement the techniques to improve sleep.
Study: NCT04854811

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Roflumilast Oral Tablet
Description: Once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast Oral Tablet
Description: Once daily for 12 weeks
Study: NCT05135481

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increased lactation support
Description: Management in group 2 will include increased lactation care both during hospital stay and post discharge.
Study: NCT06279793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long-chain n-3 fatty acids
Description: Omegaven® is a 10% fish oil emulsion supplement with a high percentage of long-chain n-3 fatty acids - mainly eicosapentaenoic acid and docosahexaenoic acid. It is a lipid emulsion supplement that optimises the fatty acid pattern in parenteral nutrition and is a source of polyunsaturated n-3 fatty acids as cell membrane components and precursors for eicosanoids.~Omegaven® is manufactured by Fresenius-Kabi, Germany and is available in 100 mL bottles for study purpose.~Each 100 mL of Omegaven® contains 10 g of fish oil (0.1 g/mL).~Timeframe:~Day -1: 0.20 g fish oil/kg BW/d; the treatment should be started 24 to 3 h before surgery, can be given as 3-6 hours infusion.~Intraoperative Day: No dose~Post OP (Day 0): 0.20 g fish oil/kg BW/d~Post OP ( Day 1 to max Day 7): 0.20 g fish oil/kg BW/d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous 0.9% Sodium Chloride
Description: Intravenous 0.9% Sodium Chloride (volume 2 mL/kg BW/d)
Study: NCT04145674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-methadone
Description: Patients will take one tablet of 25 mg d-methadone once daily at 6 pm over a period of 30 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will take one tablet of placebo once daily at 6 pm over a period of 30 days
Study: NCT05136898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UGN-102
Description: UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid under chilled conditions, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.
Study: NCT05665400

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bloomlife Lovelace FT
Description: Bloomlife Lovelace FT is a non-invasive, wireless, external measurement system used to measure accelerometer and electrophysiological signals on pregnant women with a singleton pregnancy, by acquiring biopotential signals from abdominal surface electrodes.
Study: NCT05158244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07081532
Description: Study Drug, once daily for 42 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, once daily for 42 days
Study: NCT06371404

Intervention type: DRUG
Intervention: Bavarostat
Description: Up to two injections of ≤ 5 mCi \[F18\] Bavarostat

Intervention type: DRUG
Intervention: Bavarostat
Description: Up to two injections of ≤ 5 mCi \[F18\] Bavarostat

Intervention type: DRUG
Intervention: Bavarostat
Description: Up to two injections of ≤ 5 mCi \[F18\] Bavarostat

Intervention type: DRUG
Intervention: Bavarostat
Description: Up to two injections of ≤ 5 mCi \[F18\] Bavarostat

Intervention type: DRUG
Intervention: Bavarostat
Description: Up to two injections of ≤ 5 mCi \[F18\] Bavarostat
Study: NCT05431959

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: balneotherapy
Description: immersion in Lake Hévíz, 36℃ sulphur, carbonate, calcium, magnesium, hydrogen carbonate and very light radon-content thermal-mineral water 15 times in 3 weeks 30-minute therapy sessions. The total mineral substance of the water is 754 mg/l.
Study: NCT06450626

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listening Music Intervention
Description: Participants will listen to a music playlist while vitals are monitored, along with completing a pre- and post-assessment survey (both of which are the Edmonton Symptom Assessment Scale). Participants will also be asked a set of qualitative questions about their overall experience with the music therapy session.
Study: NCT04970602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: Once the patient meets inclusion criterial, the interventional group will receive 2mg/kg methylene blue infusion within 20min, followed by 0.5mg/kg/h for 4 hours.
Study: NCT06120621

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arm 1 : VCST-phaco group , Arm 2 : phaco group.
Description: Arm 1 : VCST-phaco group , Arm 2 : phaco group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arm 1 : VCST-phaco group , Arm 2 : phaco group.
Description: Arm 1 : VCST-phaco group , Arm 2 : phaco group.
Study: NCT05016973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC
Description: 2.0mg/kg, Intravenous drip on days 1 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triplizumab
Description: 240mg, Intravenous drip on days 1 every 21 days
Study: NCT04597996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: web based education for students
Description: Web-based education will include modules on the following subjects;~* Mental health literacy knowledge level~* Improving help-seeking behavior~* Avoiding self-stigmatization in seeking psychological help
Study: NCT05892302

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Access to Asma Guardian website/app
Description: The Asma Guardian intervention application is a culturally-tailored web-platform that includes 3 tool kits. The contents of the tool kits include Asthma Specialty Care, Family Asthma Management, and Home Environmental Intervention.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Delayed Access to Asma Guardian website/app
Description: Delayed access to the website/app. The Asma Guardian intervention application is a culturally-tailored web-platform that includes 3 tool kits. The contents of the tool kits include Asthma Specialty Care, Family Asthma Management, and Home Environmental Intervention.
Study: NCT06539559

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin
Description: Based on the results of STUDY301 and STUDY304, eribulin showed outstanding therapeutic effect and tolerable adverse events in patients with metastatic breast cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Based on the results of STUDY301 and STUDY304, eribulin showed outstanding therapeutic effect and tolerable adverse events in patients with metastatic breast cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Study E2100, AVADO and RIBBON-1 found that in the first-line chemotherapy for advanced breast cancer, the addition of bevacizumab can significantly improve the efficacy of traditional chemotherapy drugs. Study RIBBON-2 and TANIA have confirmed the effectiveness of bevacizumab in the second and third line treatment of advanced HER2 negative breast cancer. Compared with chemotherapy alone, the addition of bevacizumab can prolong the PFS by 0.6 to 2.1 months.
Study: NCT05214482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: IV infusion,Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: IV infusion,Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK117
Description: IV infusion,Specified dose on specified days
Study: NCT05316610

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body Confident Athletes
Description: The Body Confident Athletes program is a five-session in-person program designed to be delivered by coaches to their athletes. Groups should be of approximately 10 girls. The organizations will work with the community partner and researchers on how to schedule the intervention over a five-week period. These sessions can replace a regular sport practice each week or an additional session can be organized by the sport organizations. Each session will take approximately 60 minutes and will consist of four phases, including The Game Plan (5 mins), The Skills (20 mins), Game Time (20 mins), and The Final Score (15 mins). A variety of activity modalities are utilized to convey learning outcomes, including group and individual activities, and discussion-, writing- and movement-based activities.
Study: NCT04187547

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tricaprilin
Description: Powder formulation will be mixed with 240 mL water and shaken until fully dispersed.~Each dosing unit of AC-SD-03 contains 20 g of the active ingredients (tricaprilin)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to AC-SD-03 will be mixed with 240 mL water and shaken until fully dispersed.
Study: NCT06247410

Intervention type: DRUG
Group type: OTHER
Intervention: Rotigotine 8Mg/24Hrs Patch
Description: Once daily patch application of one Rotigotine 8Mg/24Hrs Patch (Test or Reference) over 4 days

Intervention type: DRUG
Group type: OTHER
Intervention: Rotigotine 8Mg/24Hrs Patch
Description: Once daily patch application of one Rotigotine 8Mg/24Hrs Patch (Test or Reference) over 4 days
Study: NCT04987476

Intervention type: BIOLOGICAL
Intervention: analyzes in singles cells
Description: genome expression analyzes in single cells
Study: NCT05812534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Subjects who met the study population conditions were treated with Cadonilimab 10mg/kg + bevacizumab 7.5 mg/kg + carboplatin (AUC 5) + pemetrexed 500mg/m2. Every 3 weeks is a cycle, with a total of 4-6 cycles (the number of chemotherapy cycles is determined by the researchers). Cadonilimab 10mg/kg, bevacizumab 7.5 mg/kg and pemetrexed 500mg/m2 were then maintained until disease progression, intolerable toxicity or other causes specified in the regimen occurred. When the subject first has imaging disease progression, if the researcher judges that it is clinically beneficial and tolerant to the test drug, he will be allowed to continue treatment.
Study: NCT04877821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg on days 1 (Q3W) of the neoadjuvant and adjuvant phase of the study; IV injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: 12mg on d1-14 of Cycles 1-8 (Q3W) of the neoadjuvant phase of the study; po. Arotinib is a small molecule multi-target TKI, which exerts its effect by inhibiting angiogenesis, a critical component of tumour growth and metastasis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 100 mg/m² on day 1, 8 and 15 of Cycles 1-4 (Q3W) of the neoadjuvant phase of the study; IV injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 on days 1 of Cycles 1-4 (Q3W) of the neoadjuvant phase of the study; IV injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 90 mg/m² on day of Cycles 5-8 (Q3W) of the neoadjuvant phase of the study; IV injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m² on day of Cycles 5-8 (Q3W) of the neoadjuvant phase of the study; IV injection.